1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation

CDER Director Patrizia Cavazzoni Retires

Corrigan-Curay Named Acting Director

 
• By Sue Sutter and Derrick Gingery

Cavazzoni, who led the drugs center four-and-a-half years, decided on her own to retire at this time, sources said. The decision may have been a preemptive move knowing her time as head of CDER would have been limited, or at the very least highly challenging, under the new administration.

Sunset on blue sky
The sun is setting on Patrizia Cavazzoni's time with the US FDA. (Shutterstock)

Center for Drug Evaluation and Research Director Patrizia Cavazzoni’s retirement deepens a US Food and Drug Administration leadership void that has emerged ahead of President-elect Donald Trump’s inauguration and could herald a much larger wave of departures so the new administration could install its preferred candidates.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from HBW Insight

Accelerating Natural Options Among US FDA’s Steps For Removing Petroleum-Based Food Dyes

 
• By Malcolm Spicer

HHS Secretary Kennedy commends food companies for cooperating, but also says, “We have them on the run now and we are going to win this battle. And four years from now, we're going to have most of these products off the market.”

Beiersdorf Repositioning In China Will Get Boost From Thiamidol Launch

 
• By Eileen Francis

Beiersdorf AG hit some initial bumps with a repositioning of its business in China, but the firm is optimistic about the rollout of Thiamidol Skin Care In 2026.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”